Hong Jun Liang

Part of Beijing Strong Biotechnologies, Inc., Fuzhou Maixin Biotech Co., Ltd. engages in the production, research & development, and sales of tissue-based diagnostics, specifically IHC antibodies, reagents, and the automation of IHC and ISH. The company is based in Fuzhou, China. Fuzhou Maixin Biotech Co. was acquired by Fuzhou Maixin Biotech Co. Ltd. /Private Group/ on September 30, 2020 for $255.21 million. The Chinese company was founded in 1993. The CEO is Xiao Ya Wang.

Part of Beijing Strong Biotechnologies, Inc., Fuzhou Maixin Biotech Co., Ltd. engages in the production, research & development, and sales of tissue-based diagnostics, specifically IHC antibodies, reagents, and the automation of IHC and ISH. The company is based in Fuzhou, China. Fuzhou Maixin Biotech Co. was acquired by Fuzhou Maixin Biotech Co. Ltd. /Private Group/ on September 30, 2020 for $255.21 million. The Chinese company was founded in 1993. The CEO is Xiao Ya Wang.

Part of Beijing Strong Biotechnologies, Inc., Fuzhou Maixin Biotech Co., Ltd. engages in the production, research & development, and sales of tissue-based diagnostics, specifically IHC antibodies, reagents, and the automation of IHC and ISH. The company is based in Fuzhou, China. Fuzhou Maixin Biotech Co. was acquired by Fuzhou Maixin Biotech Co. Ltd. /Private Group/ on September 30, 2020 for $255.21 million. The Chinese company was founded in 1993. The CEO is Xiao Ya Wang.

Part of Beijing Strong Biotechnologies, Inc., Fuzhou Maixin Biotech Co., Ltd. engages in the production, research & development, and sales of tissue-based diagnostics, specifically IHC antibodies, reagents, and the automation of IHC and ISH. The company is based in Fuzhou, China. Fuzhou Maixin Biotech Co. was acquired by Fuzhou Maixin Biotech Co. Ltd. /Private Group/ on September 30, 2020 for $255.21 million. The Chinese company was founded in 1993. The CEO is Xiao Ya Wang.